News and events
august 2024
A potential new oral drug for leishmaniasis has successfully been tested in healthy humans.
June 2023
The clinical trial will run until mid 2024.
June 2023
Two members of the Tehran University of Medical Sciences (TUMS) team attended the Essentials of Clinical trials course at the LSHTM in June 2023.
Read more
November 2022
Title: “Safety and Drug Absorption of Orally Administered D121 in Healthy Adults”
(EudaCT-no: 2021-004936-27)
For more details, please see: clinicaltrials.gov/study/NCT06124144
For participating in the trial at Tübingen University (EKUT), see announcement
announcement
(EudaCT-no: 2021-004936-27)
For more details, please see: clinicaltrials.gov/study/NCT06124144
For participating in the trial at Tübingen University (EKUT), see announcement
August 22-26, 2022
Dr Katrien Van Bocxlaer (University of York) presented her research: “The development of an oral D121 treatment for cutaneous leishmaniasis”
Professor Sanjeev Krishna and Dr David Clark ( both SGUL) chaired a symposium on “Affordable diagnostics and therapeutics for neglected infections through blended 'not-for-profit' approaches with academia and industry” This session focused on talks describing new drugs, drug repurposing and diagnostics for neglected diseases.
Read more
Professor Sanjeev Krishna and Dr David Clark ( both SGUL) chaired a symposium on “Affordable diagnostics and therapeutics for neglected infections through blended 'not-for-profit' approaches with academia and industry” This session focused on talks describing new drugs, drug repurposing and diagnostics for neglected diseases.
August 1-5, 2022
This meeting, taking place every 4 years, was attended by Dr Katrien Van Bocxlaer (University of York), Dr Vanessa Yardley (LSHTM) and Ms Caroline Jansen (Oblita Therapeutics) from the TT4CL consortium.
Dr Katrien Van Bocxlaer presented her research on oral D121.
Read more
Dr Katrien Van Bocxlaer presented her research on oral D121.
March 21-24, 2022
Dr Van Boxclaer (York University) presented her research:
“The development of an oral D121 treatment for cutaneous leishmaniasis”
Dr Henry Staines (SGUL) also attended from the TT4CL consortium.
bsp.uk.net/Events
“The development of an oral D121 treatment for cutaneous leishmaniasis”
Dr Henry Staines (SGUL) also attended from the TT4CL consortium.
16-07-2019
Cutaneous leishmaniasis (CL) is a poverty related, neglected tropical disease, which is without an effective and cheap systemic treatment. The aim of TT4CL is to develop a new orally available drug for treatment of CL aimed towards registration ...
Read More
15-07-2019
TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of a Neglected Infectious (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research ...
Read More
04-07-2019
Today we were delighted to welcome specialists from across the world to @StGeorgesUni to the TT4CL kick-off meeting. It has been an honour to host this event and we look forward to developing a new Leishmaniasis drug
Read More
01-05-2019
We are delighted to announce that the grant agreement no. 815622 between the European Commission and 5 European partners and 1 Iranaian partner hes been signed on May 1, 2019. The name of the project is TT4CL, “targeted treatment for...
Read More